The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10511 tablets", a Category 1 innovative drug self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Jiangsu Hansoh Pharmaceutical Group Company Limited ("Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of hypertrophic cardiomyopathy (HCM). The specific indication will be determined after the completion of clinical research.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.22 HKD | +2.50% | +11.96% | +9.26% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.26% | 13.03B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 3692 Stock
- News Hansoh Pharmaceutical Group Company Limited
- Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice